About IBEX Technologies, Inc. 
IBEX Technologies, Inc.
Medical Specialties
IBEX Technologies Inc., through its subsidiaries, IBEX Pharmaceuticals Inc. and BioResearch Products Inc., manufactures and markets enzymes for biomedical use. The Company also manufactures and markets a series of arthritis assays, which enable the study of both the synthesis and degradation of cartilage components. It operates through the production and sale of diagnostic products segment. Its products include IB-C2C-HUSA, C2C Assay, CPII Assay, C1-2C Assay and CS-846 Assay. It provides various individual collagen associated antibodies, such as Ab1320-Rabbit Polyclonal Antibody; Type IX Collagen Antibody, and C1-2C Antibody (Col 2 3/4C short Antibody). Its diagnostic microtiter enzyme-linked immunosorbent assays include C2C-Collagen Type II Cleavage Assay; IB-C2C-HUSA-IBEX C2C Human Urine Sandwich Assay; C1,2C-Collagen Type I and II Cleavage Assay (Col 2 3/4C short antibody); CPII-Procollagen Type II C-Propeptide Assay, and CS846-Aggrecan Chondroitin Sulfate 846 Epitope Assay.
Company Coordinates 
Company Details
Suite 100, 5485 Pare Street , MONTREAL QC : H4P 1P7
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Paul Baehr
Chairman of the Board, President, Chief Executive Officer
Mr. Robert DeLuccia
Lead Independent Director
Dr. Bruce Connop
Director
Dr. Joseph Zimmermann
Director
Dr. Thomas Hecht
Independent Director
Mr. Danilo Netto
Independent Director
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jan 2024)
Net Profit:
0 Million
Medical Specialties
CAD 35 Million (Micro Cap)
9.00
NA
0.00%
-0.59
27.93%
2.48






